Toronto, Ontario – July 22, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has achieved near complete destruction (~98%) of bladder cancer in an animal model. The Company previously announced on December 9th and 23rd, 2014, respectively, of its success in destroying bladder cancer cells both in a Petri dish and in a preliminary orthotopic rat model in research performed at the University of Toledo. Theralase, in order to optimize the model, relocated it to Princess Margaret Cancer Center, University Health Network (“UHN”) under the direction of Dr. Lothar Lilge, Senior Scientist, UHN and Dr. Arkady Mandel, Chief Scientific Officer (“CSO”) of the Company. Optimization of both the formulation and purity of the lead drug, TLD-1433, by Sigma Aldridge Fine Chemicals (“SAFC”) and the wavelength of laser light used … Read More
Theralase Appoints Experienced Sales and Marketing Team to Launch Next Generation Therapeutic Laser
Toronto, Ontario – July 17, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed an experienced sales and marketing team to launch its next generation therapeutic laser. The TLC-2000 therapeutic laser with patented Cell SensingTM technology, has the unique ability of being able to “sense” injured tissue and then simultaneously deliver a precise dose of laser energy to the area healing it, safer, faster and more effectively than any other competitive product on the market. Theralase expects that this next generation technology will revolutionize the therapeutic laser industry by providing healthcare practitioners with a technology that possesses the repeatability and reproducibility that has been lacking in the field, allowing Theralase the opportunity to catapult for the first time into mainstream medicine. Theralase’s appointment of its new sales and … Read More
Theralase Appoints Director of Investor Relations
Toronto, Ontario – July 16, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed Michael Borovec as the Director of Investor Relations for the Company. Michael possesses over 10 years’ experience in investor relations and capital markets. He successfully completed the Canadian Securities Course, as well as his Series 7, 22 and 63 US licences in 2001. Michael graduated with a Business Management degree from Humber College in 1999 and an International Politics degree from York University in 2005. Roger Dumoulin-White, President and CEO, Theralase stated, “Michael has a strong working knowledge of the financial markets, security regulations and investor relations, with a demonstrated track record in serving as a corporate spokesman in the investor community. Michael’s main role with the organization will be to provide strategic corporate … Read More
FDA Findings Reinforce Need for Drug-Free Pain Management
Recent warnings from the U.S. Food and Drug Administration (FDA) have many patients and practitioners alike rethinking their approach to chronic pain management.
Plantar Fasciitis: Pain You Can’t Outrun
Plantar fasciitis is a painful disorder that affects the heel and the bottom of the foot. The condition occurs within a thick band of tissue which runs from the heel bone to the toes, the plantar fascia. Several studies into plantar fasciitis report evidence of local inflammatory changes which may contribute to the condition.1,2,3 The condition is also referred to as Jogger’s Heel because of its frequency among runners. In fact, the disorder is estimated to account for 8% of all running-related injuries.4 Plantar fasciitis is the most commonly reported cause of chronic pain beneath the heel5, and typically manifests as a sharp, stabbing pain in the bottom of the foot. Pain is normally reported as worse in the morning, but can also be triggered by long periods of standing or activity. Traditional treatments include physiotherapy and may involve the use of night splints or orthotics. In advanced cases patients … Read More
Back Pain: Ending the Viscous Cycle
Back pain is among the most common of chronic conditions, with as many as 1 in 8 Canadians reporting that they have a chronic back problem.1 The condition’s influence reaches beyond simple pain, affecting patient mobility with 31% of Canadians reporting activity limitations due to back pain.2 The economy is also unduly affected; 15% of low back pain sufferers are absent for work for over a month.3 No matter what type of pain causes the discomfort, over time chronic back pain can cause patients to limit their interactions with others to avoid discomfort or embarrassment. This can bring on depressed emotional states, as anxiety, fear, anger, fatigue and stress all combine in the body to work against the body’s natural painkillers, creating a vicious cycle of pain. Today we have no shortage of pharmaceutical options for dealing with chronic pain. However, pain medication can bring a number of unpleasant side … Read More
Theralase to Present at BIO Conference
Toronto, Ontario – June 18, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the Biotechnology Industry Organization (“BIO”) Conference on Thursday, June 18, 2015 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 10:30 am ET. About BIO Exhibition: The world’s largest biotechnology gathering, the BIO exhibition allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies. The 2015 BIO exhibition will feature more than 1,700 exhibitors and approximately 160,000 square feet. The exhibition also includes 60+ state, regional and country pavilions who in turn host many companies from their regions. About Theralase Technologies Inc. … Read More
Theralase Releases Next Generation Therapeutic Laser to Select Healthcare Practitioners and Sales Team
Toronto, Ontario – June 11, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has released commercial versions of its next generation therapeutic laser to its team of Key Opinion Leaders (“KOLs”) and Territory Sales Managers (“TSMs”) for evaluation only purposes. Formal Health Canada approval is expected in early July 2015, allowing commercial sale of the TLC-2000 in Canada. The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal the injury faster and more effectively than any other laser product on the market. Roger Dumoulin-White, President … Read More
Next Generation Therapeutic Laser Receives Safety Approval
Toronto, Ontario – June 10, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its next generation therapeutic laser, the TLC-2000, has recently received safety approval from the Canadian Standards Association (“CSA”). CSA conducted an in-depth review of the Company’s technical testing results and approved the product in accordance with the latest international medical standards, including Canadian and US standards. The CSA safety approval paves the way for formal Health Canada approval anticipated in early July 2015. The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal … Read More
Growing Your Practice with Laser Therapy
A growing number of healthcare practitioners are utilizing non-thermal laser therapy to bring clinically-proven benefits to their patients including promoting wound healing1, reducing inflammation2, and reducing pain3 right at the source. But did you know that laser treatments also provide an ideal opportunity to grow your practice and increase your revenue? In 2013, Theralase conducted a North American survey of practitioners using laser therapy on their patients. On average, most practitioners charge $50.00 per treatment and see anywhere from 100 to 400 patients per month. With a median of 200 patients per month, this translates into $10,000 in additional revenue for their practices each and every month. A growing number of private insurance plans also cover laser therapy when administered by a healthcare professional. Not only are laser treatments effective, they can be completed in only 10 minutes, making them ideal as additions to your existing patient treatment plans. Another … Read More